---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003373"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:18:23.252530+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kymera prices $275M public offering of common stock and pre-funded warrants

## Summary
- Priced public offering of 2.25M shares at $25.25 and 8.64M pre-funded warrants at $25.2499; gross proceeds ~$275M.
- Underwriters' option for additional 1.63M shares exercised in full; net proceeds estimated ~$301.1M.
- Preliminary cash, cash equivalents and marketable securities of ~$436M as of Dec 31, 2023, excluding $15M Sanofi milestone.
- Cash runway expected into first half of 2027 based on current plans and offering proceeds.
- Offering led by Morgan Stanley, J.P. Morgan, and TD Cowen; close expected Jan 9, 2024.

## SEC filing metadata
- accession: 0001193125-24-003373
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312524003373/0001193125-24-003373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312524003373/d103567d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003373
- JSON: https://secwatch.observer/filing/0001193125-24-003373.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003373.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.